Curome Biosciences is currently developing HK-660S for the treatment of Primary Sclerosing Cholangitis (PSC) and provides access to this investigational drug exclusively through ongoing clinical trials.
As HK-660S remains under investigation, Curome Biosciences is committed to ensuring a rigorous assessment of its efficacy and safety. Therefore, at this time, HK-660S is only available to patients enrolled in ongoing clinical trials, and Curome Biosciences is not considering requests for expanded access.
This policy will be periodically reviewed and may be revised at any time. Any updates regarding access to HK-660S will be communicated through appropriate channels.
Inquiries:
For inquiries regarding HK-660S and ongoing clinical trials, please contact curome@curome.co.kr.
Phone
Email
ClinicalTrials.gov URL
CuromeBiosciences
EA Policies for Single Patient